Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Recruiting · NCT06118086 · Registry updated 2026-06-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma | Neoplasms by Histologic Type, adenocarcinoma, adenoid cystic carcinoma, carcinoma, epithelial neoplasm, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-24 | NCT06118086 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Remix Therapeutics | 2 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Antoine Lacassagne | Nice | France | 83 |
| Dana Farber Cancer Research Institute | Boston | United States | 1 |
| Institut de Cancerologie Gustave-Roussy | Villejuif | France | 2 |
| MD Anderson Cancer Center | Houston | United States | 589 |
| Memorial Sloan Kettering Cancer Center | New York | United States | 1000 |
| Moffitt Cancer Center | Tampa | United States | 523 |
| Sarah Cannon Research Institute | Nashville | United States | 119 |
| University of California San Francisco Helen Diller Comprehensive Cancer Center | San Francisco | United States | 1 |
| University of Michigan Rogel Cancer Center | Ann Arbor | United States | 186 |